These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 11523556)
21. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study. Mazzariol A; Koncan R; Bahar G; Cornaglia G J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148 [TBL] [Abstract][Full Text] [Related]
22. Ketolides: the future of the macrolides? Nilius AM; Ma Z Curr Opin Pharmacol; 2002 Oct; 2(5):493-500. PubMed ID: 12324249 [TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens. Ma CX; Lv W; Li YX; Fan BZ; Han X; Kong FS; Tian JC; Cushman M; Liang JH Eur J Med Chem; 2019 May; 169():1-20. PubMed ID: 30852383 [TBL] [Abstract][Full Text] [Related]
24. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections. Yassin HM; Dever LL Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347 [TBL] [Abstract][Full Text] [Related]
25. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Lonks JR; Goldmann DA Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365 [TBL] [Abstract][Full Text] [Related]
26. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. Felmingham D J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493 [TBL] [Abstract][Full Text] [Related]
27. Ketolides in the treatment of respiratory infections. Zhanel GG; Hoban DJ Expert Opin Pharmacother; 2002 Mar; 3(3):277-97. PubMed ID: 11866679 [TBL] [Abstract][Full Text] [Related]
28. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Zhanel GG; Hisanaga T; Nichol K; Wierzbowski A; Hoban DJ Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991 [TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens. Odenholt I; Löwdin E; Cars O Antimicrob Agents Chemother; 2001 Jan; 45(1):23-9. PubMed ID: 11120939 [TBL] [Abstract][Full Text] [Related]